Search Results
-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis. 2010; 29: 1211–1218. 13 Kwon JC, Kim SH, Choi JK, et al
]. 7 Kagan VE, Yalowich JC, Borisenko GG, et al. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol. 1999; 56
leukemia. Cancer 1983; 52: 846–850. 37 Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukemia: results of conventional treatments. Experience of GIMEMA trials. Ann
. 85 Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377: 454
Deschler, B., Lübbert, M.: Acute myeloid leukemia: Epidemiology and etiology. Cancer, 2006, 107 , 2099–2107. Lübbert M. Acute myeloid leukemia: Epidemiology and etiology
elemzése).] Orv Hetil. 2016; 157: 1357–1360. [Hungarian] 27 Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107
germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 2008; 111: 4797–4808. 31 Reuther
Levine, R. L., Loriaux, M., Huntly, B. J. és mtsai The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 2005, 106
acute myeloid leukemia: identification of risk factors and development of a predictive model. Hematologica, 2008, 93 , 67–74. Martin G. Tumor lysis syndrome in patients with acute
Bross J Beitz G Chen 2001 Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia
